ArticleScientific reports2026
A novel human acute myeloid leukemia cell line SDEY-AML1 with KMT2A: MLLT3, IKZF1: EVX1 fusions exhibits high tumorigenicity in NSG mice.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Human leukemia cell lines play a crucial role in leukemia research, particularly in understanding the pathogenesis of acute leukemia and developing novel therapeutic strategies. We here describe the generation of a novel monocytic cell line SDEY-AML1, harboring alterations in KMT2A::MLLT3, IKZF1::EVX1, ETV6, and TP53 double mutations, and its biological characteristics. We established a cell line, SDEY-AML1, from the mononuclear cells isolated from the bone marrow of a patient with acute myeloid leukemia (AML-M5). Comprehensive morphological and cytogenetic characterization of SDEY-AML1 cells was performed using cytochemical staining, flow cytometry, and karyotype analysis. The molecular features of the cell line were identified by transcriptomic analysis and reverse transcription-polymerase chain reaction (PT-PCR). The proliferative capacity of the SDEY-AML1 cells was assessed using a clonogenic assay. And we conducted drug sensitivity experiments on SDEY-AML1 to tested its sensitivity to commonly used chemotherapy drugs and targeted drugs. Additionally, we created an in vivo tumor model of SDEY-AML1 cells by injecting 1×107 cells subcutaneously in NSG mice via the tail vein. The SDEY-AML1 cells were maintained in continuous culture for one year without the addition of exogenous cytokines. Cytochemical assays revealed that the cells were positive for α-naphthyl acetate esterase reactivity that was partially inhibited by sodium fluoride but negative for peroxidase and periodic acid-Schiff staining. Flow cytometry showed the expression of myeloid markers in SDEY-AML1 cells. Karyotypic analysis revealed a t(9;11) (p22;q23) translocation in SDEY-AML1 cells, mirroring the chromosomal aberrations identified in the primary leukemia cells of the patient. Genetic profiling confirmed the presence of alterations in KMT2A::MLLT3, IKZF1::EVX1, ETV6, and TP53 genes. SDEY-AML1 cultures were negative for EBV and mycoplasma. NSG mice showed tumor infiltration within 40-50 days of tail vein injection of SDEY-AML1 cells. The new AML cell line, SDEY-AML1, harbored KMT2A::MLLT3, IKZF1::EVX1, ETV6 gene alterations, and TP53 double mutations. These cells were highly tumorigenic in NSG mice. This cell line has applications in the research and development of new agents targeting KMT2A::MLLT3, IKZF1::EVX1-associated leukemia, making it a valuable tool in the study of leukemogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.